Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

Summary

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

Timeline

Start

2026-12-31

Primary completion

2030-10-31

Completion

2030-10-31

Drugs

Indications